Materialise raises 2026 profit outlook after a sharp Q2 earnings swing

Materialise has lifted its full-year 2026 adjusted earnings before interest and taxes (EBIT) guidance to a range of €12 million to €14 million ($14m to $16.3m), up from a previous range of €10m to €12m ($11.6m to $14m), after second-quarter net profit reached €3.3m ($3.9m) against €199,000 in the same period a year earlier.

Consolidated revenue for the quarter was €70.1m ($81.6m), up 8.1% year over year, while adjusted EBIT rose 26.9% to €3.9m ($4.5m). First-half revenue reached €136.3m ($158.7m), up 3.9%, and the company swung to a half-year net profit of €5.2m ($6m) from a loss of €337,000.

“In the second quarter of 2026, Materialise delivered strong financial results with consolidated revenue exceeding EUR 70 million, up 8% year over year,” said Brigitte de Vet-Veithen, Chief Executive Officer at Materialise. “Double-digit revenue growth in our Materialise Medical segment was complemented by renewed growth in our Manufacturing segment driven by strong performance in our aerospace & defense focus markets. Combined with disciplined cost management and focused execution, this revenue growth translated into a significant improvement in operational and bottomline profitability.”

Materialise Medical revenue rose 12.2% to €36.9m ($42.9m), the largest of the three segments. Manufacturing grew 6.7% to €23.6m ($27.5m) in the quarter, reversing a 1.2% decline across the first half. Software revenue fell 2.7% to €9.6m ($11.2m), and was down 2.1% for the half.

“Our net cash position further strengthened supported by consistent operating cash flow while we continued the execution of our share buyback program,” de Vet-Veithen said. Net cash stood at €74.2m ($86.4m) at June 30, up €3.4m ($4m) over the first half, with cash and equivalents of €133.7m ($155.7m). The company repurchased €5.2m ($6.1m) of shares.

“We also made meaningful progress against our strategic priorities during the quarter,” de Vet-Veithen said. “Our Materialise Software segment launched its new CO-AM offerings, we completed the previously announced divestitures of our RapidFit and Eyewear business lines, and we invested in Replasia to further expand our personalized hip care portfolio. 

“These actions reflect our commitment to sharpening our focus, strengthening our leadership in high-value applications, and building the foundation for sustainable long-term growth. With a strong balance sheet, Materialise is well positioned to capture further opportunities ahead and to create lasting value for customers, patients, partners, and shareholders.”

Materialise held its full-year revenue guidance at €273m to €283m ($317.8m) to $329.5m), a range set before the RapidFit and Eyewear disposals.

“Our solid first-half year performance reinforces our confidence in delivering on the financial targets we set for 2026,” de Vet-Veithen said. “The strategic actions we are taking to sharpen our portfolio and the targeted investments we are making across our three segments are enhancing operational performance and positioning Materialise for profitable growth. 

“Accordingly, we are reaffirming our full-year 2026 revenue guidance of 273,000 to 283,000 kEUR, fully absorbing the unfavorable revenue impact of the RapidFit and Eyewear divestments. At the same time we are increasing our full-year Adjusted EBIT guidance to a range of 12,000 to 14,000 kEUR from a previously communicated range of 10,000 to 12,000 kEUR, reflecting the strength of our execution and our continued discipline in managing costs and capital.”